Glaukos and Intratus have entered into a licensing agreement for Intratus’ noninvasive drug delivery platform, according to a press release.
Intratus’ cream-based drug formulations, designed for use in the treatment of dry eye disease, glaucoma and other corneal disorders, are applied to the outer surface of the eyelid for transdermal delivery.
Under the terms of the agreement Glaukos will have global exclusive rights to research, develop, manufacture and commercialize the platform.
“This licensing agreement adds a novel drug delivery platform using a differentiated,
Uncategorized